Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Chengdu Zenitar Biomedical Technology Co., Ltd

Clinicaltrial registered18 Nov 2026

Chengdu Zenitar Biomedical Technology Co., Ltd

18 Nov 2026: Trial registered · A Phase I Clinical Study of Oral ZL-65 Tablets in Healthy and Obese Participants With Cardiovascular Risk. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
18 Nov 2026
Title
A Phase I Clinical Study of Oral ZL-65 Tablets in Healthy and Obese Participants With Cardiovascular Risk
Conditions
Obesity With Cardiovascular Risk Study
Phase
Phase 1
Study Type
Interventional
Status
Not Yet Recruiting
Countries
Australia
Country
Australia
Reference
NCT07946783
Location
Australia
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Chengdu Zenitar Biomedical Technology Co., Ltd

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from Australia

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.